Apeiron Capital Investment Corp.
Apeiron Capital Investment Corp. (APNU): 4 pipeline candidates · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.7 months
D/E -1.08
Lead: Preclinical
4 candidates
N/A
N/A
A transparent, data-derived signal for Apeiron Capital Investment Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$631K
Quarterly Burn
$298K
Runway
6.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| active cosmetics line | Preclinical |
| disease-free universal donor alternative to donor blood | Preclinical |
| proprietary stem cell-based therapies | Preclinical |
| red blood cells | Preclinical |
Frequently asked questions
How many drug candidates are in Apeiron Capital Investment Corp.'s pipeline?
Apeiron Capital Investment Corp. (APNU) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Apeiron Capital Investment Corp.'s lead drug candidate?
Apeiron Capital Investment Corp.'s most advanced tracked candidate is active cosmetics line (Preclinical) for Skin care (anti-wrinkle, facial serum, daytime skin cream, under eye anti-wrinkle serum, high-end cream and hair vitality formulation).
What is Apeiron Capital Investment Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Apeiron Capital Investment Corp. has approximately 6.7 months of cash runway.
Who is the CEO of Apeiron Capital Investment Corp.?
Joel Shulman is the chief executive officer of Apeiron Capital Investment Corp. (APNU).
Get the full picture on Apeiron Capital Investment Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.